Meeting
2020 ASCO Virtual Scientific Program
A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer.
Authors
Christopher Jakubowski
Johns Hopkins Oncology, Baltimore, MD
Christopher Jakubowski , Natalie B Collins , Elizabeth Ann Sugar , Maureen Berg , Haihui Cao , Marios Giannakis , Elizabeth M. Jaffee , Nilofer Saba Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03711058
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4114)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4114
Abstract #
TPS4114
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.
First Author: Maliha Nusrat
Poster
2018 ASCO Annual Meeting
Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
First Author: Rod Ramchandren
Poster
2014 ASCO Annual Meeting
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
First Author: Neil Howard Segal
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.
First Author: Rachel E. Sanborn